Floatz logo

Mazdutide

Coronary Heart Disease

China National Center for Cardiovascular Diseasesprotein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Coronary Heart Disease cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
Ezetimibe
Canadian Collaborative Research Network
Phase 4BBB
Rivaroxaban
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 4BBB
SIMVASTATIN
University of Washington
Phase 4BBB
Ranolazine
OBS Pakistan
Phase 4BBB

View all 50 →

Same molecule, other indications

Mazdutide is also rated in:

obesity disorderDormant
BB
Indicative ·
70 / 100
View asset →
sleep apnea syndromeDormant
B
Indicative ·
60 / 100
View asset →
obesity disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →